Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Rating of “Hold” by Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $1.93.

Separately, D. Boral Capital dropped their target price on Carisma Therapeutics from $12.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st.

Carisma Therapeutics Stock Performance

NASDAQ:CARM opened at $0.19 on Wednesday. The company has a market capitalization of $8.02 million, a P/E ratio of -0.12 and a beta of 1.56. Carisma Therapeutics has a 1 year low of $0.16 and a 1 year high of $1.91. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The business has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.58.

Institutional Trading of Carisma Therapeutics

A hedge fund recently raised its stake in Carisma Therapeutics stock. Renaissance Technologies LLC increased its holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 11.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 231,357 shares of the company’s stock after purchasing an additional 24,600 shares during the quarter. Renaissance Technologies LLC owned 0.55% of Carisma Therapeutics worth $97,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.